Results from LIBRETTO-001 led to the US FDA regulatory approval of selpercatinib for the treatment of patients with RET fusion-positive NSCLC, RET fusion-positive thyroid cancers, and RET-mutant MTC in 2022 [146]. Here, RET is linked to medullary thyroid gland carcinoma.